Immunosuppressive treatment of rheumatic diseases during pregnancy
Rheumatic diseases have a predilection for the female sex and often become manifest during womens, childbearing years. The interaction of pregnancy and rheumatic diseases varies, some conditions benefit, others worsen in response to the immunological and hormonal alterations of pregnancy. Diseases which remain active during pregnancy may need drug treatment either for the benefit of the mother or in order to protect pregnancy and the fetus. Most often, immunosuppressive treatment is required in disorders associated with involvement of internal organs and autoimmune phenomena (Table 1).
KeywordsSystemic Lupus Erythematosus Rheumatic Disease Mycophenolate Mofetil Oral Cleft Tumor Necrosis Factor Alpha Inhibition
Unable to display preview. Download preview PDF.
- Briggs GG, Freeman RK, Yaffe SJ (1998) Drugs in pregnancy and lactation, 5th edn. Williams & Wilkins. Baltimore, pp 272c-279cGoogle Scholar
- Brent RL (1998) Leflunomide as an example of a modern approach to product labelling for reproductive effects: a category X drug based on pharmacokinetic data. Teratology 58: 445Google Scholar
- Fraser FC, Sajoo A (1985) Teratogenic potential of corticosteroids in humans. Teratology 51: 4546Google Scholar
- Gaughan WJ, Moritz MJ, Radomski JS, Burke JF Jr, Armenti VT (1996) National Transplantation Pregnancy Registry: report on outcomes in cyclosporine-treated female kidney transplant recipients with an interval from transplant to pregnancy of greater than five years. Am J Kidney Dis 28: 266–269PubMedCrossRefGoogle Scholar
- Goroir BP, Peppel K, Silva M, Beutler B (1992) The biosynthesis of tumor necrosis factor during pregnancy: studies with a CAT reporter transgene and TNF inhibitors. Eur Cytokine Network 3: 533–537Google Scholar
- Harris EN, Pierangeli SS (1998) Utilization of intravenous immunoglobulin therapy to treat recurrent pregnancy loss in the antiphospholipid syndrome: a review. Scand J Rheumatol (Suppl) 107: 97–102Google Scholar
- Katz JA, Lichtenstein GR, Keenan GF, Healy DE, Jacobs SJ (2001) Outcome of pregnancy in women receiving remicade (Infliximab) for the treatment of Crohn’s disease or rheumatoid arthritis. American Gastroenterological Association, Digestive Disease Week, Atlanta, April 2001, Abstract 366Google Scholar
- Kraus AM (1975) Congenital cataract and maternal steroid injection. J Pediatr Ophthalmol Strabismus 12: 107–108Google Scholar
- Le Thi Huong D, Wechsler B, Bletry O, Vauthier-Brouzes D, Lefebvre G, Piette JC (2001) A study of 75 pregnancies in patients with antiphospholipid syndrome. J Rheumatol 28: 2025–2030Google Scholar
- Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L, Friesen MH, Jacobson S, Kasapinovic S, Chang D, Diav-Citrin O, Chitayat D, Nulman I, Einarson TR, Koren G (2000) Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 62: 385–392PubMedCrossRefGoogle Scholar